Antivenin (latrodectus mactans) - Biologic Drug Details

Summary for antivenin (latrodectus mactans)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antivenin (latrodectus mactans) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antivenin (latrodectus mactans) Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for antivenin (latrodectus mactans) Derived from Patent Text Search

No patents found based on company disclosures

Antivenin (latrodectus mactans) Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Antivenin (Latrodectus Mactans)

Introduction

Antivenin (Latrodectus Mactans), also known as black widow spider antivenom, is a biologic drug used to treat envenomations caused by black widow spider bites. This article delves into the market dynamics and financial trajectory of this critical medication.

Clinical Significance and Demand

Black widow spider bites, although relatively rare, pose a significant health risk, with over 2500 cases reported to American poison control centers annually[4]. The severe pain and systemic symptoms associated with these bites create a consistent demand for effective treatments. Antivenin (Latrodectus Mactans) is one of the few specific treatments available, making it a vital component in emergency medicine.

Current Market Scenario

The market for Antivenin (Latrodectus Mactans) is characterized by limited suppliers and high demand during peak seasons. The primary supplier, Merck & Co., has historically restricted the availability of the antivenom due to insufficient supply, leading to delays in treatment and increased healthcare costs[1].

Pricing and Cost Considerations

The cost of Antivenin (Latrodectus Mactans) is significant, with a single dose of 6000 units costing around $39 for cash-paying customers. This price can be a barrier for many patients, especially those without insurance coverage[2].

Patient Assistance Programs

Despite the high cost, there are limited patient assistance programs available for this medication. This lack of financial support exacerbates the accessibility issues for patients in need of this antivenom[2].

Efficacy and Safety

The efficacy of Antivenin (Latrodectus Mactans) has been demonstrated in several clinical trials. For instance, a phase 3 trial showed that the experimental equine Fab 2 antibody preparation (Antivenin Latrodectus Equine Immune F(ab')2) had fewer treatment failures compared to placebo, with a significant reduction in pain intensity[1].

However, the use of antivenom is often withheld due to fears of acute hypersensitivity reactions and serum sickness. Despite these concerns, recent cases have shown that antivenom can be used safely and effectively[4].

Market Challenges

Supply Chain Issues

The restricted availability of Antivenin (Latrodectus Mactans) due to supply chain issues is a major challenge. Patients often have to wait 24 to 48 hours or more for the antivenom, prolonging their pain and increasing healthcare expenses[1].

Adverse Reactions

The risk of acute severe allergic reactions and serum sickness associated with antivenom use remains a significant concern. This has led to underutilization of the antivenom, with only 3.8% of patients with clinical effects attributed to latrodectism receiving antivenom from 2000 to 2008[3].

Emerging Alternatives

New Formulations

Research into new formulations, such as the experimental equine Fab 2 antibody preparation (Antivenin Latrodectus Equine Immune F(ab')2), aims to reduce adverse reactions while maintaining efficacy. These developments could potentially increase the market share and acceptance of antivenom treatments[1].

Analatro®

Another emerging alternative is Analatro®, which has shown fewer adverse reactions in clinical trials compared to the traditional Merck IgG product. This could be a game-changer in the market, offering a safer and more reliable treatment option[3].

Financial Trajectory

Revenue Streams

The revenue generated from Antivenin (Latrodectus Mactans) is substantial, given its high price point and consistent demand. However, the limited supply and restricted availability can cap the potential revenue growth.

Cost Savings

Effective use of antivenom can lead to significant cost savings in the long run by reducing the need for prolonged hospital stays, high doses of benzodiazepines and opioids, and other supportive treatments[1].

Future Projections

As new formulations and safer alternatives become available, the market for Antivenin (Latrodectus Mactans) is expected to expand. Increased accessibility and reduced fear of adverse reactions could drive up demand, leading to higher revenues.

Regulatory Environment

The regulatory environment plays a crucial role in the market dynamics of Antivenin (Latrodectus Mactans). FDA approvals and guidelines are essential for the introduction of new formulations and ensuring the safety and efficacy of existing treatments[1].

Conclusion

The market for Antivenin (Latrodectus Mactans) is complex, influenced by factors such as supply chain issues, adverse reaction risks, and emerging alternatives. Despite these challenges, the drug remains a critical treatment for black widow spider envenomations.

Key Takeaways

• Consistent Demand: Black widow spider bites create a steady demand for antivenom.
• Supply Chain Issues: Restricted availability affects treatment timing and costs.
• Efficacy and Safety: Antivenom is effective but comes with risks of adverse reactions.
• Emerging Alternatives: New formulations like Antivenin Latrodectus Equine Immune F(ab')2 and Analatro® offer potential improvements.
• Financial Trajectory: Revenue is substantial but capped by supply issues; new alternatives could drive growth.

FAQs

Q: What is the primary use of Antivenin (Latrodectus Mactans)?

A: Antivenin (Latrodectus Mactans) is used to treat patients with symptoms due to bites by the black widow spider (Latrodectus mactans)[5].

Q: Why is the availability of Antivenin (Latrodectus Mactans) restricted?

A: The availability is restricted due to insufficient supply, leading to delays in treatment and increased healthcare costs[1].

Q: What are the risks associated with using Antivenin (Latrodectus Mactans)?

A: The risks include acute hypersensitivity reactions and serum sickness, which have led to underutilization of the antivenom[3].

Q: Are there any emerging alternatives to Antivenin (Latrodectus Mactans)?

A: Yes, new formulations like Antivenin Latrodectus Equine Immune F(ab')2 and Analatro® are being developed to reduce adverse reactions while maintaining efficacy[1][3].

Q: How does the cost of Antivenin (Latrodectus Mactans) impact its use?

A: The high cost of the antivenom can be a barrier for many patients, especially those without insurance coverage, and there are limited patient assistance programs available[2].

Sources

1. The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.
2. Antivenin (Latrodectus Mactans) Prices, Coupons, Copay Cards & Patient Assistance.
3. Treatments for Latrodectism—A Systematic Review on Their Clinical Efficacy.
4. The treatment of black widow spider envenomation with antivenin.
5. ANTIVENIN - Merck.com.